STOCKHOLM – June 26, 2025 – Inify Laboratories, an ultra-modern laboratory service that provides cancer diagnostics within pathology, is proud to announce a significant milestone with the successful processing of its first ever UK case.
Under a newly established contract with Parkside Suite, (owned by Frimley Health NHS Foundation Trust). Inify has completed the diagnostic reporting of prostate biopsy samples for the first UK patient, achieving a turnaround time of just five working days from biopsy to report.
This landmark case underscores Inify Laboratories' commitment to delivering fast, reliable, and high-quality pathology services, while supporting health systems in streamlining prostate cancer pathways and enhancing patient care. The collaboration reflects a shared dedication to innovation and efficiency in diagnostic services across the UK.
"Inify provides a great service backed up by a great team. I cannot speak highly enough about what they have to offer, there is clearly a huge future for this model of histology processing and using AI to speed up and improve diagnostic accuracy. It’s been an absolute pleasure working with the team in both the UK and Sweden. Long may it continue," says Simon Bott, Consultant Urological Surgeon, Frimley Parkside Suite in Surrey, UK.
"We are incredibly grateful to the team at Parkside & Frimley Health NHS Foundation Trust for their time, diligence, and partnership in ensuring all governance processes were fully in place, enabling the highest standard of care for the patient," says Kate Bucknall, Managing Director, UK at Inify Laboratories. "This successful first case marks an exciting leap forward. We look forward to continuing this structured and collaborative approach with further private and NHS hospitals to deliver a high-quality, reliable, and sustainable diagnostic service across the country."
“This milestone represents the next step on our establishment journey in the UK, where we are currently fitting out a brand-new domestic laboratory. I am impressed by the forward-looking mindset we’ve experienced in our dialogue with UK stakeholders so far. It raises my optimism even further about improving healthcare substantially, together,” says Fredrik Palm, CEO of Inify Laboratories.